<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2014020316466N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-04-17</date_registration>
      <primary_sponsor>Dentofacial Deformities Research Center of Shahid Beheshti University of Medical Science</primary_sponsor>
      <public_title>Prevention of orthodontic pain</public_title>
      <acronym></acronym>
      <scientific_title>A comparison between efficacy of ketoprofen and benzocaine patches on post orthodontic pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2014-02-24</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/15398</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Orthodontic pain.</hc_freetext>
      <i_freetext>Intervention 1: benzocaine patch, each 6 hours 1 patch until 3 days&#13;
   The patches contained: Benzocaine(C9H11NO2) ,propylen glycol,di chloro methan,aspartam,poly vynil prolidine,ethanol and hydroxy proppyl methyl cellulose.Solvent casting was performed to make patches.At first the materials are weighted and solve in one proper solvent,then are mixed by magnetic mixer ( Heidolph stirrer, model:MR3001K, Germany)for 30 minutes. If no sediment observed, and the solution is clear ,each 50 cc will be placed in the same sized plates for 48hours under the hood for evaporation.To prevent contamination, a funnel should be placed above the plates; with reducing the speed of dissolving, the contents of the films would not migrate and the final homogenity of the film will be maintained.Hydroxy propyl methyl cellulose  and polyvinyl prolidin will provide proper viscousity for the film to adher to oral mucosa.Propyl glycol is used for lavigation of Benzocaine or Ketoprufrn.Dichloro methan and ethanol solvents will be used to disolve the polymers after lavigation.To sweeten the films and making their taste more acceptable, Aspartam will be added.When the apperance of the provided material(film) is acceptable, they are cut into 0.5 x 1.5 cm pieces and hold in periapical radiographic film covers.In each section 2 films are placed. For each patient 12 Benzocaine and 12 ketoprufen patches are needed and the patients have to use them for 3 days.&#13;
After placement of elastic separators in proximal of right and left 1st molars, the patients will be instructed to use the keto and benzo patches on both sides of the arch simultaneously to perform a split-mouth study.Since pain is subjective , split-mouth study reduces the individual differences. Pilot study was performed to make certain that the two patches do not mix to reduce the study value.&#13;
The patients and the operator would not know which patch contain which element and the patches will be divided to A and B to make the study a double blind one and the patches will be randomly assigned to right and left sides by coin method.The amount of pain will be assessed by VAS scores(0 to 100) and the patients will fill the questioners at the determined times : 2,6 ,12 and 24hours, day 2 and day 3( at 10 am and 6 pm) after separator placement. The amount of pain in scores will be calculated for the two patches and the difference reported. Intervention 2: ketoprpfen patch , each 6 hours 1 patch until 3 days&#13;
The patches contained: Ketoprufen(C16H14O3), propylen glycol,di chloro methan,aspartam,poly vynil prolidine,ethanol and hydroxy proppyl methyl cellulose.Solvent casting was performed to make patches.At first the materials are weighted and solve in one proper solvent,then are mixed by magnetic mixer ( Heidolph stirrer, model:MR3001K, Germany)for 30 minutes. If no sediment observed, and the solution is clear ,each 50 cc will be placed in the same sized plates for 48hours under the hood for evaporation.To prevent contamination, a funnel should be placed above the plates; with reducing the speed of dissolving, the contents of the films would not migrate and the final homogenity of the film will be maintained.Hydroxy propyl methyl cellulose  and polyvinyl prolidin will provide proper viscousity for the film to adher to oral mucosa.Propyl glycol is used for lavigation of Benzocaine or Ketoprufrn.Dichloro methan and ethanol solvents will be used to disolve the polymers after lavigation.To sweeten the films and making their taste more acceptable, Aspartam will be added.When the apperance of the provided material(film) is acceptable, they are cut into 0.5 x 1.5 cm pieces and hold in periapical radiographic film covers.In each section 2 films are placed. For each patient 12 Benzocaine and 12 ketoprufen patches are needed and the patients have to use them for 3 days.&#13;
After placement of elastic separators in proximal of right and left 1st molars, the patients will be instructed to use the keto and benzo patches on both sides of the arch simultaneously to perform a split-mouth study.Since pain is subjective , split-mouth study reduces the individual differences. Pilot study was performed to make certain that the two patches do not mix to reduce the study value.&#13;
The patients and the operator would not know which patch contain which element and the patches will be divided to A and B to make the study a double blind one and the patches will be randomly assigned to right and left sides by coin method.The amount of pain will be assessed by VAS scores(0 to 100) and the patients will fill the questioners at the determined times : 2,6 ,12 and 24hours, day 2 and day 3( at 10 am and 6 pm) after separator placement. The amount of pain in scores will be calculated for the two patches and the difference reported.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamide Motaharifard- Dr. Naseh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Chamran Exp.way,Daneshjoo blvd-dehkhod street</address>
        <city>Tehran-Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19834</zip>
        <telephone>+98 21 2240 3070</telephone>
        <email>motaharifar.h@gmail.com</email>
        <affiliation>Shahid Beheshti Universiy of Medical Sciences-Private office</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ladan Eslamian- Seyed Alireza Mortazavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Chamran Exp.way, Daneshjoo blvd-Chamran Exp.way, Across Vali-asr Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19834</zip>
        <telephone>+98 21 2990 2304</telephone>
        <email>leslamian@gmail.com; alirmortazavi@yahoo.com</email>
        <affiliation>Shahi Beheshti University of Medical Sciences, Dental &amp; pharmacology schools</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: participants, in good general health without any reported systematic diseases; no concurrent use of analgesics and anti-inflammatory drugs; requiring banding of posterior teeth and placement of two or more elastomeric separators as a part of orthodontic treatment; caries-free dentition with healthy periodontium and without any endodontic problems in the posterior part of the mouth; presence of antagonist teeth in the opposite arch and absence of posterior open bite and interdental spaces. Patients were excluded from the study if they used analgesics and anti-inflammatory drugs during the study, did not complete the questionnaire, did not use or improperly used benzocaine or ketoprofen patches,or removed  elastomeric separators.</inclusion_criteria>
      <agemin>11 years</agemin>
      <agemax>35 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>XXI</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Factors influencing health status and contact with health services</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>benzocaine patch, each 6 hours 1 patch until 3 days&#13;
   The patches contained: Benzocaine(C9H11NO2) ,propylen glycol,di chloro methan,aspartam,poly vynil prolidine,ethanol and hydroxy proppyl methyl cellulose.Solvent casting was performed to make patches.At first the materials are weighted and solve in one proper solvent,then are mixed by magnetic mixer ( Heidolph stirrer, model:MR3001K, Germany)for 30 minutes. If no sediment observed, and the solution is clear ,each 50 cc will be placed in the same sized plates for 48hours under the hood for evaporation.To prevent contamination, a funnel should be placed above the plates; with reducing the speed of dissolving, the contents of the films would not migrate and the final homogenity of the film will be maintained.Hydroxy propyl methyl cellulose  and polyvinyl prolidin will provide proper viscousity for the film to adher to oral mucosa.Propyl glycol is used for lavigation of Benzocaine or Ketoprufrn.Dichloro methan and ethanol solvents will be used to disolve the polymers after lavigation.To sweeten the films and making their taste more acceptable, Aspartam will be added.When the apperance of the provided material(film) is acceptable, they are cut into 0.5 x 1.5 cm pieces and hold in periapical radiographic film covers.In each section 2 films are placed. For each patient 12 Benzocaine and 12 ketoprufen patches are needed and the patients have to use them for 3 days.&#13;
After placement of elastic separators in proximal of right and left 1st molars, the patients will be instructed to use the keto and benzo patches on both sides of the arch simultaneously to perform a split-mouth study.Since pain is subjective , split-mouth study reduces the individual differences. Pilot study was performed to make certain that the two patches do not mix to reduce the study value.&#13;
The patients and the operator would not know which patch contain which element and the patches will be divided to A and B to make the study a double blind one and the patches will be randomly assigned to right and left sides by coin method.The amount of pain will be assessed by VAS scores(0 to 100) and the patients will fill the questioners at the determined times : 2,6 ,12 and 24hours, day 2 and day 3( at 10 am and 6 pm) after separator placement. The amount of pain in scores will be calculated for the two patches and the difference reported.</i_keyword>
      <i_keyword>ketoprpfen patch , each 6 hours 1 patch until 3 days&#13;
The patches contained: Ketoprufen(C16H14O3), propylen glycol,di chloro methan,aspartam,poly vynil prolidine,ethanol and hydroxy proppyl methyl cellulose.Solvent casting was performed to make patches.At first the materials are weighted and solve in one proper solvent,then are mixed by magnetic mixer ( Heidolph stirrer, model:MR3001K, Germany)for 30 minutes. If no sediment observed, and the solution is clear ,each 50 cc will be placed in the same sized plates for 48hours under the hood for evaporation.To prevent contamination, a funnel should be placed above the plates; with reducing the speed of dissolving, the contents of the films would not migrate and the final homogenity of the film will be maintained.Hydroxy propyl methyl cellulose  and polyvinyl prolidin will provide proper viscousity for the film to adher to oral mucosa.Propyl glycol is used for lavigation of Benzocaine or Ketoprufrn.Dichloro methan and ethanol solvents will be used to disolve the polymers after lavigation.To sweeten the films and making their taste more acceptable, Aspartam will be added.When the apperance of the provided material(film) is acceptable, they are cut into 0.5 x 1.5 cm pieces and hold in periapical radiographic film covers.In each section 2 films are placed. For each patient 12 Benzocaine and 12 ketoprufen patches are needed and the patients have to use them for 3 days.&#13;
After placement of elastic separators in proximal of right and left 1st molars, the patients will be instructed to use the keto and benzo patches on both sides of the arch simultaneously to perform a split-mouth study.Since pain is subjective , split-mouth study reduces the individual differences. Pilot study was performed to make certain that the two patches do not mix to reduce the study value.&#13;
The patients and the operator would not know which patch contain which element and the patches will be divided to A and B to make the study a double blind one and the patches will be randomly assigned to right and left sides by coin method.The amount of pain will be assessed by VAS scores(0 to 100) and the patients will fill the questioners at the determined times : 2,6 ,12 and 24hours, day 2 and day 3( at 10 am and 6 pm) after separator placement. The amount of pain in scores will be calculated for the two patches and the difference reported.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: 2 h, 6h, 24h, day2(6 pm), day3(10am and 6 pm) and day7(10 am and 6 pm). Method of measurement: 100 scores  visual analogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Production. Timepoint: 2 h, 6h, 24h, day2(6 pm), day3(10am and 6 pm) and day7(10 am and 6 pm). Method of measurement: visual analogue scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dentofacial Deformities Research Center of Shahid Beheshti University of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-04-21</approval_date>
        <contact_name>shahid beheshti university of medical science-dental univerity</contact_name>
        <contact_address>Chamran Exp.way,Daneshjoo blvd tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
